

PHARMACEUTICAL 2023

PARDES BIOSCIENCES INC. Rank 106 of 446









RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of PARDES BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PARDES BIOSCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of PARDES BIOSCIENCES INC. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 150% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	200,402
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,425
Liabilities, Non-Current	0
Other Assets	219
Other Compr. Net Income	-24
Other Expenses	0
Other Liabilities	0
Other Net Income	3,183
Other Revenues	0
Property and Equipment	0
Research and Development	70,350
Selling, General and Administrative Expense	29,467

Output Variable	Value in 1000 USD
Assets	200,621
Liabilities	20,425
Expenses	99,817
Revenues	0
Stockholders Equity	180,196
Net Income	-96,634
Comprehensive Net Income	-96,646
Economic Capital Ratio	193%

